StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Tuesday morning. The brokerage issued a hold rating on the stock.

Several other equities analysts have also commented on the stock. Northland Capmk lowered shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 12th. Brookline Capital Management reaffirmed a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. HC Wainwright reduced their target price on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Finally, Northland Securities reaffirmed a “market perform” rating and set a $2.00 target price on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Price Performance

Shares of NASDAQ:ONCT opened at $1.14 on Tuesday. Oncternal Therapeutics has a one year low of $1.03 and a one year high of $13.14. The company’s fifty day moving average price is $1.37 and its 200-day moving average price is $4.91. The firm has a market capitalization of $3.37 million, a price-to-earnings ratio of -0.10 and a beta of 1.33.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC bought a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned 0.84% of Oncternal Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.